DCC0455 |
Acetaminosalol |
Analgesic, antipyretic, and anti-inflammatory agent |
|
DCC0456 |
Acetobixan |
Novel Inhibitor of Cellulose Synthesis |
|
DCC0457 |
Acetophenazine Dimaleate |
Antipsychotic, targeting the dopamine D2 receptor |
|
DCC0458 |
Achn975 |
Novel potent and selective LpxC inhibitor |
|
DCC0459 |
Acp-1n |
Novel Inhibitor of BRD4-Driven Nucleoporin NUP210 Expression, Attenuating Colorectal Cancer Growth |
|
DCC0460 |
Activator-3 |
Novel potent activator of pan-AMPK, enhancing AMPK phosphorylation by upstream kinase LKB1 and protecting AMPK complex against dephosphorylation by PP2C |
|
DCC0461 |
Acy-1083 |
Novel selective HDAC6 inhibitor, showing 260-fold selectivity towards HDAC6 vs other HDACs |
|
DCC0462 |
Ad-10942-8 |
Novel selective USP8 inhibitor (USP8 IC50 2.1 μM; USP7 >50μM) |
|
DCC0463 |
Ad-227 |
Novel potent inhibitor of the MDM2-p53 interaction |
|
DCC0464 |
Adamantylamphetamine Hydrochloride |
Potential antidepressant and anti-Parkinson agent |
|
DCC0465 |
Adamantylmethamphetamine Hcl |
Potential antidepressant and anti-Parkinson agent |
|
DCC0466 |
Adamts-5 Inhibitor
Featured
|
Selective inhibitor of ADAMTS-5 (A disintegrin and metalloproteinase with thrombospondin motifs 5 or aggrecanase-2) |
|
DCC0467 |
Adasgc |
Novel Hsp40-Hsp70 chaperone complex inhibitor, inhibiting the Hsp40-stimulated ATPase activity of the Hsp70 chaperone, with a K i of ~10 μM |
|
DCC0468 |
Adep-2b |
Novel inhibitor of ClpXP complexes, causing extremely rapid dissociation of ClpXP complexes, preventing ClpX rebinding following spontaneous dissociation |
|
DCC0469 |
Aderbasib |
Novel sheddase inhibitor, inhibiting the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity |
|
DCC0470 |
Adinazolam Mesylate |
Antidepressant and anxiolytic agent, binding to peripheral-type benzodiazepine receptors that interact allosterically with GABA receptors as an agonist to produce inhibitory effects |
|
DCC0471 |
Ad-isec |
Novel Potent Mutant p53 Rescuing Agent |
|
DCC0472 |
Adjuvant |
Novel antibiotic adjuvant, exhibiting as high as 4096-fold potentiation of multiple classes of antibiotics toward critical Gram-negative superbugs |
|
DCC0473 |
Adjuvant Nada |
Novel antibiotic adjuvant, exhibiting as high as 4096-fold potentiation of multiple classes of antibiotics toward critical Gram-negative superbugs |
|
DCC0474 |
Adp-2341 |
Novel soluble analog of FiVe1 |
|
DCC0475 |
Adp-hpd |
Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitor |
|
DCC0476 |
Adr-925 |
Active iron-chelating metabolite of dexrazoxane |
|
DCC0477 |
Adrenaline Sulfate |
Nonselective agonist of all adrenergic receptors, including the major subtypes alpha1, alpha2, ß1, ß2, and ß3 |
|
DCC0478 |
Ads-103317 |
Novel Inhibitor of EGF-EGFR Interactions |
|
DCC0479 |
Ads-j1 |
Inhibitor of semen-derived amyloid fibril formation, blocking fibril-mediated enhancement of HIV-1 infection |
|
DCC0480 |
Adt-061 |
Novel PDE10 inhibitor, reducing oncogenic β-catenin, suppressing TCF/LEF transcription |
|
DCC0481 |
Adtl-ei1712 |
The first selective dual-target inhibitor of ERK1 and ERK5 |
|
DCC0482 |
Adx61623 |
Novel Nonsteroidal Negative Allosteric Modulator of Follicle-Stimulating Hormone Receptor (FSHR) |
|
DCC0483 |
Adx68692 |
Novel Nonsteroidal Negative Allosteric Modulator of Follicle-Stimulating Hormone Receptor (FSHR) |
|
DCC0484 |
Adx68693 |
Novel inhibitor of hFSHR (104 nM) and hLHR (314 nM), showing no activity with hTSHR at 30 μM |
|